Global Parkinson’s Disease Market to Hit $5.31 Billion by 2030 at 8% CAGR

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Expansion In Market Value Is Forecasted For The Parkinson’s Disease Market Between 2026 And 2030?

The market size for Parkinson’s disease has experienced significant growth in recent years. It is anticipated to increase from $3.62 billion in 2025 to $3.92 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 8.2%. The historical expansion can be attributed to several factors, including the restricted availability of treatment options for disease progression, a predominant reliance on levodopa-centric therapy, delayed diagnoses due to overlapping symptoms, a scarcity of specialized movement disorder clinics, and inconsistent access to advanced surgical interventions.

The Parkinson’s disease market is anticipated to show strong expansion in the coming years. It is forecast to grow to $5.32 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 8.0%. This projected growth during the forecast period stems from the development of novel dopamine and non-dopamine therapies, an increasing aging population, greater uptake of deep brain stimulation procedures, a heightened focus on personalized medicine approaches, and the proliferation of neurology specialty clinics. Key trends during this period include the rising adoption of combination drug therapies, an escalating use of deep brain stimulation procedures, advancements in early-stage diagnosis and intervention, the broadening of multidisciplinary Parkinson’s care programs, and enhanced symptom management through individualized treatment plans.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21247&type=smp

Which Key Drivers Are Affecting The Parkinson’s Disease Market Development?

The growing incidence of neurodegenerative diseases is anticipated to drive expansion in the parkinson’s disease market. These conditions encompass a range of disorders marked by the gradual deterioration and functional decline of neurons within the brain and nervous system. Their rising occurrence is linked to an aging demographic, genetic predispositions, environmental factors, enhanced diagnostic methods, increasing chronic health issues, and evolving lifestyles. Parkinson’s disease contributes significantly to advancing comprehension of neurodegenerative conditions, offering crucial insights into their fundamental mechanisms, potential treatment targets, and the formulation of novel therapeutic strategies. For example, the National Institutes of Health (NIH), a key US government medical research agency, predicted in 2025 that the prevalence of Parkinson’s disease for 2050 would be approximately 267 cases per 100,000 people, ranging from 230 to 320. Consequently, the expanding prevalence of neurodegenerative diseases is fueling growth within the parkinson’s disease market.

How Are Segments Identified Within The Parkinson’s Disease Market Segment Framework?

The parkinson’s disease market covered in this report is segmented –

1) By Drug Class: Dopamine Agonists, Catechol-O-Methyltransferase Inhibitors, Monoamine Oxidase B Inhibitors, Anticholinergics, Carbidopa-Levodopa, Other Drug Classes

2) By Route Of Administration: Oral, Injectable, Intestinal infusion, Subcutaneous, Other Routes Of Administrations

3) By Distribution Channel: Retail Pharmacies, Hospital Pharmacies, Online Pharmacies

4) By Patient Care Setting: Clinics, Hospitals

Subsegments:

1) By Dopamine Agonists: Ergot Derivatives, Non-Ergot Derivatives

2) By Catechol-O-Methyltransferase (COMT) Inhibitors: Entacapone, Tolcapone, Opicapone

3) By Monoamine Oxidase B (MAO-B) Inhibitors: Selegiline, Rasagiline, Safinamide

4) By Anticholinergics: Trihexyphenidyl, Benztropine, Procyclidine

5) By Carbidopa-Levodopa: Immediate-Release Formulation, Extended-Release Formulation, Inhaled And Intestinal Gel Formulations

6) By Other Drug Classes: Amantadine And Derivatives, Adenosine A2A Receptor Antagonists, Glutamate Antagonists

What Trends Are Transforming The Parkinson’s Disease Market?

Leading companies within the parkinson’s disease market are concentrating on developing innovative solutions, such as levodopa-based therapy, to enhance motor function and provide continuous symptom management for individuals with advanced parkinson’s disease. Levodopa-based therapy utilizes levodopa, a medication that converts into dopamine in the brain, to improve motor function and alleviate symptoms of Parkinson’s disease. For instance, in October 2024, AbbVie Inc., a US-based biopharmaceutical company, received US Food and Drug Administration (FDA) approval for VYALEV, a combination therapy containing levodopa and carbidopa, specifically designed for the treatment of Parkinson’s disease. Its formulation aims to improve the efficacy of levodopa by inhibiting its breakdown before reaching the brain, consequently increasing dopamine levels. This medication is effective in managing motor symptoms of Parkinson’s disease, including tremors, rigidity, and bradykinesia, which in turn enhances a patient’s ability to perform daily tasks. It is recognized as a key therapeutic solution for patients with Parkinson’s disease experiencing motor fluctuations.

Who Are The Companies Competing Within The Parkinson’s Disease Market?

Major companies operating in the parkinson’s disease market are Roche Holding AG, AbbVie Inc., Novo Nordisk A/S, Takeda Pharmaceutical Company Limited, UCB S.A., Eisai Co. Ltd., Kyowa Kirin Co. Ltd., Amneal Pharmaceuticals Inc., Neurocrine Biosciences Inc., Supernus Pharmaceuticals Inc., Sunovion Pharmaceuticals Inc., Intracellular Therapies Inc., Voyager Therapeutics Inc., Sage Therapeutics Inc., Adamas Pharmaceuticals Inc., Sun Pharma Advanced Research Company Ltd., Neuraly Inc., Mitsubishi Tanabe Pharma Corporation, Athira Pharma Inc., VistaGen Therapeutics Inc.

Get The Full Parkinson’s Disease Market Report:

https://www.thebusinessresearchcompany.com/report/parkinsons-disease-global-market-report

Which Region Leads The Parkinson’s Disease Market In Overall Market Size?

North America was the largest region in the parkinson’s disease market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the parkinson’s disease market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Parkinson’s Disease Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/parkinsons-disease-global-market-report

Browse Through More Reports Similar to the Global Parkinson’s Disease Market 2026, By The Business Research Company

Esophageal Cancer Market Report 2026

https://www.thebusinessresearchcompany.com/report/esophageal-cancer-global-market-report

Head And Neck Cancer Diagnostics Market Report

https://www.thebusinessresearchcompany.com/report/head-and-neck-cancer-diagnostics-global-market-report

Oral Cancer Treatment Market Report

https://www.thebusinessresearchcompany.com/report/oral-cancer-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795